Showing results (161-170 of 242) with videos related to

Sort By:
Pageof 25
Nature Communications|December 13, 2019
Extracellular matrix hydrogel derived from decellularized tissues enables endodermal organoid cultureGiovanni Giuseppe Giobbe, Claire Crowley, Camilla Luni, et al.
Lancet (London, England)|October 20, 2025
Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trialMaria De Santis, Joan Palou Redorta, Hiroyuki Nishiyama, et al.
European Urology Oncology|July 20, 2025
Patient-reported Outcomes in KEYLYNK-010: Pembrolizumab Plus Olaparib Versus Abiraterone or Enzalutamide for Participants with Biomarker-unselected, Previously Treated Metastatic Castration-resistant Prostate CancerNiven Mehra, Emmanuel S Antonarakis, Se Hoon Park, et al.
Clinical and Experimental Rheumatology|December 18, 2020
Efficacy and safety of baricitinib in 446 patients with rheumatoid arthritis: a real-life multicentre studyGiacomo Maria Guidelli, Ombretta Viapiana, Nicoletta Luciano, et al.
Rheumatology (Oxford, England)|May 15, 2024
Rituximab retention rate in systemic sclerosis: a long term real-life multicentre studyGiacomo De Luca, Enrico De Lorenzis, Corrado Campochiaro, et al.
The Lancet. Oncology|December 15, 2023
Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised, controlled, phase 3 studyEnrique Grande, José Á Arranz, Maria De Santis, et al.
European Journal of Cancer (Oxford, England : 1990)|April 8, 2014
Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus PanelJohn M Fitzpatrick, Joaquim Bellmunt, Karim Fizazi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 5, 2025
Pembrolizumab Plus Docetaxel Versus Docetaxel for Previously Treated Metastatic Castration-Resistant Prostate Cancer: The Randomized, Double-Blind, Phase III KEYNOTE-921 TrialDaniel P Petrylak, Raffaele Ratta, Nobuaki Matsubara, et al.
The Lancet. Oncology|December 15, 2023
Atezolizumab monotherapy versus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis from a randomised, controlled, phase 3 studyAristotelis Bamias, Ian D Davis, Matthew D Galsky, et al.
Frontiers in Immunology|April 16, 2014
Genome-wide analysis of DNA methylation, copy number variation, and gene expression in monozygotic twins discordant for primary biliary cirrhosisCarlo Selmi, Francesca Cavaciocchi, Ana Lleo, et al.
Pageof 25